MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:31Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Prostaglandin analogs]]
			[[Category:Glaucoma medications]]
			[[Category:Ocular hypotensive agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #67

2026-05-23T03:42:09Z

parser-claude batch MedTemplate pre-fill, Top 300 #67

New page

{{MedTemplate
| generic = Latanoprost
| brand = Xalatan, Xelpros
| structure =
| classes = [[:Category:Prostaglandin_analogs|Prostaglandin F2α analog]], [[:Category:Glaucoma_medications|Glaucoma medication]], [[:Category:Ocular_hypotensive_agents|Ocular hypotensive agent]]
| uses = <vote slug="primary-open-angle-glaucoma-use">Primary open-angle glaucoma</vote>, <vote slug="ocular-hypertension-use">Ocular hypertension</vote>
| starting_dose = 1 drop in the affected eye(s) once daily in the evening
| preparations = 0.005% ophthalmic solution (50 mcg/mL); typical 2.5 mL bottle
| fda_max = 1 drop/eye/day (more frequent dosing reduces efficacy)
| pill_id =
| routes = Topical ophthalmic
| onset = IOP lowering at 3-4 hours; maximum at 8-12 hours
| duration = 24 hours
| halflife = ~17 minutes (free acid, the active form, in aqueous humor)<ref name="xalatan-label">FDA Prescribing Information, Xalatan (latanoprost), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020597s056lbl.pdf</ref>
| bioavailability = Topical; minimal systemic absorption<ref name="xalatan-label" />
| pregnancy = Limited data; weigh against alternatives, though systemic exposure is low.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="latanoprost-mech-claim">Latanoprost is an isopropyl ester prodrug hydrolyzed in the cornea to its free acid, a selective FP-receptor (prostaglandin F2α receptor) agonist; FP activation remodels the ciliary muscle extracellular matrix and increases uveoscleral aqueous outflow, lowering intraocular pressure by ~25-35%.</vote> Once-daily evening dosing is more effective than morning. Characteristic adverse effects: iris pigmentation darkening (especially mixed-color irides; permanent), periocular skin pigmentation, eyelash growth (used cosmetically for the closely-related bimatoprost), conjunctival hyperemia<ref name="xalatan-label" />.
}}

== References ==
<references />

Latanoprost - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #67